Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral α-Amylase Enzyme Replacement for the Treatment of Diabetic Polyneuropathy

NCT07148804 is registered in ClinicalTrials.gov with Helwan University as lead sponsor.

NCT NCT07148804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07148804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral α-Amylase Enzyme Replacement for the Treatment of Diabetic Polyneuropathy
Lead sponsor
Helwan University
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2023
Completion date
August 15, 2024
Enrollment
83 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic polyneuropathy